BR112016030728A2 - método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença - Google Patents
método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doençaInfo
- Publication number
- BR112016030728A2 BR112016030728A2 BR112016030728A BR112016030728A BR112016030728A2 BR 112016030728 A2 BR112016030728 A2 BR 112016030728A2 BR 112016030728 A BR112016030728 A BR 112016030728A BR 112016030728 A BR112016030728 A BR 112016030728A BR 112016030728 A2 BR112016030728 A2 BR 112016030728A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic composition
- treating
- preventing
- disease
- composition
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 101150007028 HTRA1 gene Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229940021993 prophylactic vaccine Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014902493A AU2014902493A0 (en) | 2014-06-30 | Helicobacter therapeutic | |
| PCT/AU2015/000380 WO2016000022A1 (en) | 2014-06-30 | 2015-06-30 | Helicobacter therapeutic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016030728A2 true BR112016030728A2 (pt) | 2018-02-20 |
Family
ID=55018143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016030728A BR112016030728A2 (pt) | 2014-06-30 | 2015-06-30 | método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170165347A1 (enExample) |
| EP (1) | EP3160492A4 (enExample) |
| JP (1) | JP6634444B2 (enExample) |
| KR (1) | KR102481455B1 (enExample) |
| CN (2) | CN113694191A (enExample) |
| AU (1) | AU2015283805B2 (enExample) |
| BR (1) | BR112016030728A2 (enExample) |
| RU (1) | RU2017100658A (enExample) |
| WO (1) | WO2016000022A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101885460B1 (ko) | 2017-02-07 | 2018-08-03 | 두산중공업 주식회사 | 가스터빈용 프리 스월러 장치 |
| CN108531468B (zh) * | 2018-02-24 | 2020-07-17 | 广东工业大学 | 编码重组幽门螺杆菌丝氨酸蛋白酶的基因、卵黄抗体与应用 |
| KR102500799B1 (ko) | 2018-03-09 | 2023-02-20 | 삼성디스플레이 주식회사 | 트랜지스터 기판 및 이를 구비하는 표시 장치 |
| RU2746590C1 (ru) * | 2020-10-12 | 2021-04-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Вятский государственный университет" | Способ эрадикации бактерий Helicobacter pylori при экспериментальном хеликобактериозе у конвенциональных белых мышей и средство для его осуществления |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| EP0740704A1 (en) | 1994-01-27 | 1996-11-06 | University Of Massachusetts Medical Center | Immunization by inoculation of dna transcription unit |
| US5939400A (en) | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| WO1997044446A1 (en) | 1996-05-24 | 1997-11-27 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
| EP0977864A2 (en) * | 1997-04-25 | 2000-02-09 | Genelabs Technologies, Inc. | Antigenic composition and method of detection for helicobacter pylori |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| GB9808720D0 (en) * | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| US6585975B1 (en) * | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
| AUPP684998A0 (en) * | 1998-10-30 | 1998-11-26 | Murdoch Institute for Research into Birth Defects Limited, The | A method of recombination and agents useful for same |
| US6319224B1 (en) | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| DE60124526D1 (de) * | 2000-04-27 | 2006-12-28 | Max Planck Gesellschaft | Methode zur identifizierung von helicobacter antigenen |
| US7015033B1 (en) * | 2000-05-25 | 2006-03-21 | Aventis Pasteur Limited | Co-expression of recombination proteins |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| FR2815544B1 (fr) | 2000-10-23 | 2003-02-14 | Poudres & Explosifs Ste Nale | Seringue sans aiguille securisee a architecture compacte |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| EP1622933A2 (en) * | 2003-04-22 | 2006-02-08 | Intercell AG | H. pylori antigens |
| US7868139B2 (en) * | 2006-01-24 | 2011-01-11 | Uab Research Foundation | Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases |
| CN101443353A (zh) * | 2006-03-15 | 2009-05-27 | Csir公司 | 谷氨酰胺合成酶活性的调节 |
| US20110250221A1 (en) * | 2007-08-24 | 2011-10-13 | University Of Wollongong | Group A Streptococcus Pharmaceutical Compositions and Methods Thereof |
| WO2010068413A1 (en) * | 2008-11-25 | 2010-06-17 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
-
2015
- 2015-06-30 BR BR112016030728A patent/BR112016030728A2/pt not_active Application Discontinuation
- 2015-06-30 CN CN202110962088.5A patent/CN113694191A/zh active Pending
- 2015-06-30 US US15/321,933 patent/US20170165347A1/en not_active Abandoned
- 2015-06-30 RU RU2017100658A patent/RU2017100658A/ru not_active Application Discontinuation
- 2015-06-30 CN CN201580035276.6A patent/CN106573038A/zh active Pending
- 2015-06-30 WO PCT/AU2015/000380 patent/WO2016000022A1/en not_active Ceased
- 2015-06-30 KR KR1020177002217A patent/KR102481455B1/ko active Active
- 2015-06-30 JP JP2017519730A patent/JP6634444B2/ja active Active
- 2015-06-30 AU AU2015283805A patent/AU2015283805B2/en active Active
- 2015-06-30 EP EP15814180.4A patent/EP3160492A4/en not_active Ceased
-
2019
- 2019-09-18 US US16/574,625 patent/US20200108135A1/en not_active Abandoned
-
2021
- 2021-08-27 US US17/459,715 patent/US11819546B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3160492A4 (en) | 2018-01-03 |
| CN113694191A (zh) | 2021-11-26 |
| CN106573038A (zh) | 2017-04-19 |
| AU2015283805B2 (en) | 2021-02-25 |
| US20220193216A1 (en) | 2022-06-23 |
| KR102481455B1 (ko) | 2022-12-26 |
| WO2016000022A1 (en) | 2016-01-07 |
| US20200108135A1 (en) | 2020-04-09 |
| RU2017100658A3 (enExample) | 2019-02-19 |
| JP6634444B2 (ja) | 2020-01-22 |
| EP3160492A1 (en) | 2017-05-03 |
| RU2017100658A (ru) | 2018-07-30 |
| US11819546B2 (en) | 2023-11-21 |
| US20170165347A1 (en) | 2017-06-15 |
| JP2017521490A (ja) | 2017-08-03 |
| AU2015283805A1 (en) | 2017-01-05 |
| KR20170016989A (ko) | 2017-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| BR112017001310A2 (pt) | coronavírus | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| CL2015001772A1 (es) | Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma. | |
| MX383484B (es) | Método para tratar el cáncer. | |
| BR112015018877A2 (pt) | Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
| GT201800102A (es) | Polipéptidos que inhiben cd4ol | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| BR112016028316A2 (pt) | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento | |
| ZA201701000B (en) | Attenuated bovine coronavirus and related vaccines | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| BR112016024096A2 (pt) | novo bacteriófago e composição compreendendo o mesmo | |
| BR112017019358A2 (pt) | combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular | |
| BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
| MX2015008944A (es) | Proceso de liofilizacion. | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| BR112016030728A2 (pt) | método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença | |
| BR112016002462A8 (pt) | Métodos para melhorar os sintomas da asma usando benralizumabe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |